Selecta Biosciences Inc reports results for the quarter ended in September - Earnings Summary

Cartesian Therapeutics

03/11/2022 13:32

* Selecta Biosciences Inc  SELB.OQ  reported a quarterly
adjusted
loss of 5 cents​​ per share for the quarter ended in September.
The mean expectation of seven analysts for the quarter was for a
loss of one cent per share.
    * Revenue fell 15.2% to $20.71 million from a year ago;
analysts
expected $25.21 million. 
    * The mean earnings estimate of analysts had risen by
about 71.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Selecta Biosciences Inc shares had fallen by 0.6% this
quarter and lost 50.0% so far this year.
    * Wall Street's median 12-month price target for Selecta
Biosciences Inc is $7.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 01:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.01          -0.05          Missed
 Jun. 30 2022      -0.08          0.06           Beat
 Mar. 31 2022      -0.11          0.23           Beat
 Dec. 31 2021      -0.07          0.03           Beat